Companies · Biotechnology

Ceres Nanosciences, Inc.

MANASSAS · Biotechnology

Diligence memoA one-page analyst read on Ceres Nanosciences, Inc. — recommendation, valuation, rhythm, risks.
$8.0M
Total raised · real
2
Rounds
1.7×
Latest step-up
Top 49%
Sector rank · raised
Series A
Latest stage · inferred · Thu Sep 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Ceres Nanosciences, Inc. looks fair against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.43× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
  • Within the normal band (143% of peer median) for its niche.
At-risk
  • Last raise 3.8 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Ceres Nanosciences, Inc. is one of 4293 Biotechnology companies tracked from MANASSAS. By capital raised it ranks mid-pack (ahead of 52% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(c)
Reg D exemption
1
Investors (latest)
2022-09-01
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2017-01-23 Raised $3.0M (real) Modeled valuation $133M (est)$3.0M$133MSeed2017Series A · 2022-09-01 Raised $5.0M (real) Modeled valuation $64M (est)$5.0M$64MSeries A2022+$5.0MCumulative $8.0M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.0M · 2017
Series A$5.0M · 2022

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$63.5M
Base estimate est.
$5.5M
Conservative case
$209.7M
Upside case
$22.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $133.2M · 2017-01-232017Series A · modeled $63.5M · 2022-09-012022
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
3.8 yr
Elapsed time used
3.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
67 mo
Avg between rounds
$1.4M/yr
Capital velocity
9.4 yr
On record since
2017
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.1× above median
This company$8.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.9× of median
This company$5.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 1.0× of median
This company$63.5M
Sector median$64.2M

Raised more than 52% of sector peers (real $). Modeled value above 50% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #111 of 303.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.3M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $216.2M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $207.1M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.5M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $189.2M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.2M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.9M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $184.0M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.4M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.4M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.4M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $169.0M (est)Ceres Nanosciences, Inc. (this company) Raised $8.0M · modeled $63.5M (est)Ceres Nanosciences, Inc.
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.3M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$216.2M4.87×
Adient Medical, Inc.Series A$18.2M$207.1M4.67×
Entegrion IncSeries A$22.7M$191.5M4.32×
BCD Bioscience, Inc.Series A$16.4M$189.2M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.2M4.20×
MicroByre, Inc.Series A$16.1M$185.9M4.19×
Cardiac Insight, Inc.Series A$38.1M$184.0M4.15×
Cardiac Implants LLCSeries A$13.5M$178.4M4.02×
Abintus Bio, Inc.Series A$13.7M$177.4M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.4M3.98×
Mazen Animal Health Inc.Series A$13.5M$169.0M3.81×
Ceres Nanosciences, Inc. this companySeries A$8.0M$63.5M1.43×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.0M2017-01-23$15.0M$133.2M90%
Series A$5.0M2022-09-01$22.7M$63.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.0M2017-01-23
    • First recorded raise — entered as Seed.
    • 1 investor on this round.
  2. Series A$5.0M2022-09-01
    • Raised again after 67 mo — slower than the ~14 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
    • 1 investor on this round.
Intelligence
2028 ~Q2
Modeled next raise · ~67mo cadence
$8.3M
Modeled next size est.range $5.4M$13.3M
1.7×
Last step-up
$1.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Tom Miller3 other2017-01
Scott Gazelle2 other2017-01
Emanuel Petricoin1 other2022-09
Ian Wright1 other2022-09
Emanuel Petricoin III2017-01
Ross Dunlap2017-01
Thomas Dunlap2017-01
Registry & provenance

Ceres Nanosciences, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1697394
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
eLum Technologies, Inc.BiotechnologySeries A$8.0M$71.5Msame sector · same stage
Arcion Therapeutics, Inc.BiotechnologySeries A$8.2M$54.2Msame sector · same stage
Naked Biome, Inc.BiotechnologySeries A$7.8M$59.9Msame sector · same stage
Rejuvitas, Inc.BiotechnologySeries A$8.3M$63.6Msame sector · same stage
DermOQ, Inc.BiotechnologySeries A$8.4M$55.2Msame sector · same stage
Oncopia Therapeutics, LLCBiotechnologySeries A$8.4M$54.2Msame sector · same stage
Gliacure, Inc.BiotechnologySeries A$8.4M$57.0Msame sector · same stage
Window Therapeutics, Inc.BiotechnologySeries A$7.5M$57.3Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Cerecin Inc.BiotechnologySeries C$34.1M87%
NanoView Biosciences, Inc.BiotechnologySeries A$41.3M87%
Cerebrotech Medical Systems, Inc.BiotechnologySeed$137.3M87%
Cereius, Inc.BiotechnologySeed$44.4M86%
NanoCellect Biomedical, Inc.BiotechnologySeries B$322.9M86%
Celularity Inc.BiotechnologySeries C$3.2B86%
CIRC Biosciences, Inc.BiotechnologySeries B$54.7M86%
Integrated Nano-Technologies, Inc.BiotechnologySeries A$227.8M86%
Frequently asked
How much funding has Ceres Nanosciences, Inc. raised?
Ceres Nanosciences, Inc. has raised approximately $8.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Ceres Nanosciences, Inc.'s estimated valuation?
Provath's modeled valuation for Ceres Nanosciences, Inc. is approximately $63.5M (modeled range $5.5M–$209.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Ceres Nanosciences, Inc. at?
Ceres Nanosciences, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Sep 01.
What does Ceres Nanosciences, Inc. do and where is it based?
Ceres Nanosciences, Inc. operates in the Biotechnology sector, based in MANASSAS.
Explore related

See where Ceres Nanosciences, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Ceres Nanosciences, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.